REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Five-membered Hetero Ring Containing At Least One Nitrogen Ring Atom (e.g., 1,2,3-triazoles, Etc.) > 1,3,4-thiadiazoles (including Hydrogenated) > Polycyclo Ring System Having The Thiazole Ring As One Of The Cyclos > Bicyclo Ring System Having The Thiazole Ring As One Of The Cyclos Bicyclo Ring System Having The Thiazole Ring As One Of The CyclosBicyclo Ring System Having The Thiazole Ring As One Of The Cyclos patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/25/07 - 20070021478 - Benzothiazolyl derivatives wherein R1, R2, R3 R3a and R3b are as provided in the description, and pharmaceutically acceptable salts thereof, for use in the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors such as obesity. ... 01/25/07 - 20070021477 - Cyclohexylglycine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes The present invention is directed to novel cyclohexylglycine derivatives which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also ... 01/04/07 - 20070004787 - 4-substituted and 7-substituted indoles, benzofurans, benzothiophenes, benzimidazoles, benzoxazoles, and benzothiazoles and methods for making same Disclosed are 4-substituted and 7-substituted indoles, benzofurans, benzothiophenes, benzimidazoles, benzoxazoles, and benzothiazoles. Also disclosed are methods for making 4-substituted and 7-substituted indoles, benzofurans, benzothiophenes, benzimidazoles, benzoxazoles, and benzothiazoles, including those having the formulae. The methods include contacting a 4-substituted-6,7-dihydro indole, benzofuran, benzothiophene, benzimidazole, benzoxazole, or benzothiazole compound or a 7-substituted-4,5-dihydro ... 12/14/06 - 20060281797 - Neurorestoration with r(+) pramipexole Formulations and methods of use thereof for restoring neuronal, muscular (cardiac and striated) and/or retinal tissue function in children and adults afflicted with chronic neurodegenerative diseases, such as neurodegenerative movement disorders and ataxias, seizure disorders, motor neuron diseases, and inflammatory demyelinating disorders, are described herein. Examples of disorders include Alzheimer's ... 11/23/06 - 20060264483 - Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors Selected sulfonylalkanoylamino hydroxyethylamine sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, ... 11/16/06 - 20060258722 - Condensed ring compound R1 is an optionally substituted hydroxy group, and a salt thereof. ... 10/19/06 - 20060235061 - Methods of using benzothiophenone derivatives to treat cancer or inflammation Methods of using benzothiophenone derivatives to treat cancer or inflammation in a mammal and pharmaceutical compositions containing such derivatives are disclosed. ... 10/05/06 - 20060223869 - Compounds for the reduction of excessive food intake The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake. ... 10/05/06 - 20060223868 - Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) wherein R1, n, R3, R4, R7, R8 and P are as defined in the specification, salts, solvates or solvated salts thereof, processes for their preparation, new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and the use of said compounds in therapy. ... 09/14/06 - 20060205796 - Method for treating pain or pruritis by administering opinoid receptor agonist comprising 2-phenylbenzothiazoling derivative wherein R is an alkyl having an amino group as a substituent; and R1 is acyl. ... 08/24/06 - 20060189667 - Ppar-activating compound and pharmaceutical composition comprising the compound (wherein each of R1 and R2, which may be identical to or different from each other, represents a hydrogen atom, a methyl group, or an ethyl group; each of R3a, R3b, R4a, and R4b, which may be identical to or different from each other, represents a hydrogen atom, a halogen ... 07/27/06 - 20060167068 - Method of treating self-injurious behavior with glutamate modulating agents Inventors have made the surprising discovery that glutamate modulating agents are useful for treating borderline personality disorder and self-injurious behavior. Methods of treating borderline personality and self-injurious behavior are provided herein by administering a glutamate modulating agent to a patient are included herein. The invention also includes combination methods of ... 07/06/06 - 20060148866 - Novel process for preparing pramipexole and its optical isomeric mixture by reduction with sodium triacetoxyborohydride A novel process is provided for producing pramipexole base or its optical isomeric mixture as defined hereinabove i.e. (R,S)-2-amino-6-propyl-4,5,6,7-tetrahydrobenzothiazole avoiding the use of borane tetrahydrofuran complex and using a more convenient reducing agent like sodium triacetoxyborohydride instead. The provided process comprises reacting the starting material (S)-2,6-diamino-4,5,6,7-tetrahydrobenzothiazole or its optical isomeric ... 06/22/06 - 20060135574 - Novel uses for estrogen beta agonists This invention provides methods for treating cognitive diseases or disorders and symptoms thereof with estrogen beta selective agonists. ... 06/22/06 - 20060135573 - Benzothiazole-4,7-diones and benzoxazole-4,7-diones with substituents in position 5 or 6 and method for production thereof A subject of the invention is a selective process for the preparation of derivatives of benzothiazole-4,7-diones and benzoxazole-4,7-diones monosubstituted in position 5 or in position 6 by an amino group itself optionally substituted. Said derivatives are inhibitors of the Cdc25 phosphatases and can be used for preparing medicaments intended to ... 06/08/06 - 20060122242 - 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders A class of 2-aryloxy-2-arylalkanoic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, ... 05/25/06 - 20060111408 - Therapeutic benzothiazole compounds X is O or S; and R1, R3-R6 are as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them. ... 05/25/06 - 20060111407 - Association between a heterocyclic compound stimulating lipid and carbohydrate metabolisms and an antioxidant agent for treating obesity The invention relates to a combination comprising a compound favouring lipid and carbohydrate metabolisms and an antioxidant agent and to pharmaceutical compositioins comprising the combination. ... 05/18/06 - 20060106075 - Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity in free or salt or solvate form, wherein X has the meaning indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the β2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. ... 05/18/06 - 20060106074 - Er-b-selective ligands The invention relates to novel compounds having the general formula: (1) wherein X is O or S which are useful as selective ER-β ligands in the treatment or prophylaxis of Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis or prostate cancer. ... 05/11/06 - 20060100256 - Process for preparing 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole 2,6-diamino-4,5,6,7-tetrahydro-benzothiazole, which is useful for making pramipexole, is made by: (i) reacting bromine with a solution of 4-acetamido-cyclohexanone in water to produce 2-bromo-4-acetamido-cyclohexanone; (ii) after step (i), adding thiourea to produce 6-acetyl amino-2-amino-4,5,6,7-tetrahydro-benzthiazole; (iii) after step (ii), adding an aqueous solution of hydrobromic acid to produce 2,6-diamino-4,5,6,7-tetrahydro-benzthiazole dihydrobromide; and (iv) ... 05/11/06 - 20060100255 - Substituted indolealkanoic acids derivative and formulations containing same for use in the treatment of diabetic complications Disclosed is a compound of the formula (I) its hydrates and/or pharmaceutically acceptable salts, which are useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds and methods of treatment employing the compounds, as well as methods for their preparation. ... 04/06/06 - 20060074114 - Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids Disclosed are methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis, the methods comprising administration of substituted indolealkanoic acids to patients in need of such treatment. Also disclosed are such compounds useful in the treatment of angiogenesis, hyperglycemia, hyperlipidemia and chronic complications arising from diabetes mellitus. Also ... 03/23/06 - 20060063817 - New betamimetics for the treatment of respiratory complaints wherein the groups n, m, B, X and R1 may have the meanings given in the claims and specification, processes for preparing them and their use as pharmaceutical compositions, particularly as pharmaceutical compositions for the treatment of respiratory complaints. ... 03/23/06 - 20060063816 - 2-arylbenzothiazole derivatives Y and Z are independently selected from any of the following: C1-C6 straight chain, branched or cyclic substituted or unsubstituted alkyl group, Y and Z can be taken together to form a cyclic alkyl or hetereoalkyl group wherein in addition to N the hetereoalkyl group comprises a heteroatom selected from ... 03/16/06 - 20060058361 - Therapeutic diphenyl ether ligands or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are defined in the specification; and, in which the dashed line represents an optional double bond. The invention is also directed to methods of treating, diagnosing, and preventing disorders of the central nervous system that are associated ... 03/16/06 - 20060058360 - Propanamine derivatives as serotonin and norepinephrine reuptake inhibitors There is provided a heretoaryloxy/thio 3-substituted propanamine compound of formula (I) wherein A is selected from —)— and —S—; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each ... 02/23/06 - 20060040997 - Benzthiazole-3 oxides useful for the treatment of proliferative disorders each R9 and R10 is independently hydrocarbyl, or R9 and R10 together form part of a saturated or unsaturated ring system, optionally containing up to two heteroatoms selected from N, O, and S; in the preparation of a medicament for treating a proliferative disorder. ... 02/23/06 - 20060040996 - Benzothiazole-and benzoxazole-4, 7-dione derivatives and their use as dcd25 phosphatase inhibitors The invention concerns the use as cdc25 phosphatase inhibitors, in particular cdc25-C phosphatase, and CD45 phosphatase, of compounds of general formula (I), wherein: W represents O or S. In accordance with the invention, the compounds of general formula (I) can in particular be used for preparing a medicine for cancer ... 02/16/06 - 20060035946 - Amyloid-binding, metal-chelating agents The present invention relates to the diagnosis, prevention, and treatment of pathophysiological conditions associated with amyloid accumulation. Bifunctional therapeutic molecules and contrast imaging agents exhibiting a high affinity for amyloid deposits, and pharmaceutical compositions thereof are described. The invention also provides methods of using these bifunctional molecules, contrast imaging agents, ... 02/09/06 - 20060030607 - Compounds for the reduction of excessive food intake The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake. ... 01/19/06 - 20060014810 - Durable antimicrobial leather A leather having durable antimicrobial efficacy after at least 5 washing is disclosed. The leather is treated in-situ with an antimicrobial composition containing both a bactericide and a fungicide. The bactericide and the fungicide are exhausted into the leather thereby providing durable antimicrobial activity. ... 01/12/06 - 20060009501 - Materials and methods for immune system stimulation The subject invention concerns a novel polysaccharide. RR1 is an α-D-glucan polysaccharide composed of a (1→4) linked back bone and (1→6) linked branches, which has been isolated from a medicinal herb, Tinospora cordifolia. RR1 exhibits unique immune-stimulating properties, is non-cytotoxic, and non-proliferating to normal lymphocytes, as well as tumor cell ... 12/22/05 - 20050282875 - Pyrrolidinium derivatives are disclosed; as well as processes for their preparation, pharmaceutical compositions comprising them and their use in therapy as antagonists of M3 muscarinic receptors. ... 10/27/05 - 20050239851 - Substituted benzoxazoles as estrogenic agents R1, R2, R2a, R3, R3a, and R4, and X as defined in the specification, or a pharmaceutically acceptable salt thereof. ... 09/22/05 - 20050209291 - Amino benzothiazole compounds with nos inhibitory activity The present invention provides novel amino benzothiazole compounds, compositions comprising these compounds and methods of using these compounds as neuroprotectants. In particular, the compounds described in the present invention are useful for treating stroke and neuropathic pain. ... 09/15/05 - 20050203153 - Phthalimide carboxylic acid derivatives The present invention relates to phthalimide carboxylic acid derivatives of formula (I), methods for their preparation, pharmaceutical compositions containing them and their use in medicine, specifically in the treatment of cancer. (I), wherein X is O or S; R1 is a phthalimide carboxylic acid group of formula (II). R is ... 08/11/05 - 20050176786 - Bicyclic pyrazolo protein kinase modulators The present invention provides novel bicyclic pyrazolo kinase modulators and methods of using the novel bicyclic pyrazolo kinase modulators to treat diseases mediated by kinase activity. ... 08/04/05 - 20050171168 - Use of riluzole for the treatment of multiple sclerosis Methods and compositions for the treatment of multiple sclerosis comprising riluzole (6-(trifluoromethoxy)-benzothiazolamine) are disclosed herein. ... 07/21/05 - 20050159462 - Imidazole 4-carboxamide compounds with adenosine deaminase inhibiting activity Imidazole compounds having adenosine deaminase inhibitory activity represented by the formula (I): wherein R1 is optionally substituted aryl or optionally substituted heteroaryl, R2 is lower alkyl; R3 is hydroxy or protected hydroxy; X is O or S; and -A- is lower alkylene, its prodrug, or their salt. The compounds are ... ### FreshPatents.com Support |